作者
Elizabeth C Nowak, J Louise Lines, Frederick S Varn, Jie Deng, Aurelien Sarde, Rodwell Mabaera, Anna Kuta, Isabelle Le Mercier, Chao Cheng, Randolph J Noelle
发表日期
2017/3
来源
Immunological reviews
卷号
276
期号
1
页码范围
66-79
简介
Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V‐domain Ig‐containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti‐VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
学术搜索中的文章
EC Nowak, JL Lines, FS Varn, J Deng, A Sarde… - Immunological reviews, 2017